Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 15/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 14/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 12/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 12/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 12/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 12/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 1.00 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218780 | 1.00 | HDAC8 (1.00) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL4258833 | 0.88 | HDAC8 (1.00) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL996809 | 0.75 | HDAC1 (0.60) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL28881222 | 0.74 | HDAC8 (0.77) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL8131488 | 0.73 | HDAC8 (1.00) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL1249448 | 0.73 | HDAC8 (1.00) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL11731153 | 0.73 | LMNA (0.59) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL10457552 | 0.70 | HDAC1 (0.67) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL10449499 | 0.70 | HDAC1 (0.67) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL2073321 | 0.70 | ATM (1.00) | HDAC8HDAC10HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | claimed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | claimed |
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2135620-A1 | OCULAR HYPOTENSIVE AGENT COMPRISING COMPOUND CAPABLE OF INHIBITING HISTONE DEACETYLASE AS ACTIVE INGREDIENT | Santen Pharmaceutical Co., Ltd (JP) | 2009-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | HDAC8 7/4885HDAC10 11/4885HDAC3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.